Malignant syphilis in an immunocompetent female patient*

Camila Bueno Requena1
Juliana Polizel Ocanha1
Mariangela Esther Alencar Marques1
Cinthia Rosane Orasmo1
Silvia Regina Catharino Sartore Barraviera1
Silvio Alencar Marques1

Abstract: Malignant syphilis is an uncommon manifestation of secondary syphilis, in which necrotic lesions may be associated with systemic signs and symptoms. Generally it occurs in an immunosuppressed patient, mainly HIV-infected, but might be observed on those who have normal immune response. Since there is an exponential increase in the number of syphilis cases, more diagnoses of malignant syphilis must be expected. We report a case in an immunocompetent female patient.

Keywords: Allergy and immunology; Syphilis; Syphilis, cutaneous; Therapeutics; Treatment outcome

INTRODUCTION

Early malignant syphilis is a rare form of secondary syphilis, more frequently associated with HIV – co-infected patients.1-2 Malnutrition, abusive consumption of alcohol and concomitant debilitating illnesses are other possible predisposing factors.1,3,4 More rarely, it can occur in immunocompetent patient. It was first described by Bazin in 1859 (apud Tucker et al. 2009) as a nodular variant of syphilis.5 It is different from classical manifestations of secondary syphilis for its greater severity and lesion morphology. Cutaneous lesions of malignant syphilis are preceded by prodromal fever, cephalalgia, arthralgia and myalgia of variable intensity. They are characterized by the onset of pleomorphic pustules, nodules and ulcers.6 The mucosas may be compromised and the patient may present associated enlargement of lymph nodes and hepatosplenomegaly.

Before the advent of HIV infection, malignant syphilis was extremely rare; between 1900 and 1988 only 14 cases had been published in English language literature. At present, it is estimated that up to 7% of syphilis cases in HIV/aids-infected patients meet the criteria for malignant syphilis, and not rarely they are the first clinical manifestation revealing a hidden HIV infection.7

The authors report a case of early malignant syphilis in young immunocompetent patient being monitored for psoriasis vulgaris controlled with topical treatment.
Malignant syphilis in an immunocompetent female patient

Malignant syphilis: papulous and ulcerated papulonodular lesions on the face

Malignant syphilis: papulous, ulcerated papulous and ulcerated nodular lesions covered by scab on forearm

Malignant syphilis: detail of papulous and ulcerated nodular lesions

Malignant syphilis: ulcerated lesion with superficial crust and dense lichenoid lymphohistiocytic infiltrate, rich in plasmocytes. HE 10X

Malignant syphilis: detail of dermal infiltrate and endarteritis with fibrin microthrombi. HE 20X

Malignant syphilis: Treponema pallidum immunomarked with polyclonal antibody. IHQ 60X

Early malignant syphilis: Treponema pallidum immunomarked with polyclonal antibody. IHQ 60X

The patient was treated with 2,400,000 units of benzathine penicillin, in a total of three series with an interval of one week between the series. She presented intense Jarisch-Herxheimer reaction after the first application of penicillin. Lesion healing was fast and serology showed VDRL titre fell to 1/16 after three months of treatment and negativation after nine months.
DISCUSSION

After the first description in 1859, for many decades doubts remained if malignant syphilis was part of the secondary syphilis spectrum or a manifestation of tertiary syphilis. This issue was clarified by studies conducted by Haslund and Neisser, published in 1897. The malignant syphilis is distinguished from classical secondary syphilis by the general clinical picture more exuberant and severe, pleomorphic lesions and fundamentally by the presence of ulceronecrotic lesions. It is distinguished from tertiary syphilis by the larger number of lesions, repercussion in the general health condition and for being morphologically distinct from chronic gummas, both clinically and histologically.

Epidemiological data show the recrudescence of syphilis cases, mainly in men who have sex with other men and among HIV-infected patients. In Germany it was observed that among 11,368 HIV-infected patients, 151 (1.3%) presented syphilis during follow-up and 11 of them (7.3%) had malignant syphilis. These data draw attention to possible higher occurrence of the disease in the different services. A study of 21 cases where the patients were coinfected by HIV showed higher incidence in male patients (62%), median age 34 years and, in 80% of the cases, CD4 count > 200 cells/mm³. In 33% there was ocular involvement and in 24% mucosas were compromised.

Strictly speaking, the pathogenesis of malignant syphilis is unknown, but the prevalent opinion is that in those coinfected by HIV the immunodeficiency favors the predominance of the virulence of the agent in the agent-host contest. This reasoning is coherent with its occurrence in those who have the abusive use of alcohol or illicit drugs, malnutrition or debilitating disease as a cofactor. The occurrence of malignant syphilis, as in the case described, in immunocompetent patient, raises the possibility, already considered by other authors, of infection by more virulent strains of Treponema, which, although possible, is difficult to be demonstrated.

When there is clinical suspicion of malignant syphilis, confirmation of the diagnosis will be supported by three criteria: clinical and histopathological characteristics; presence of high titre of antibodies in VDRL or a similar test; intense and severe Jarisch-Herxheimer reaction and rapid resolution of lesions with adequate therapy. The investigation of immunodeficiency inducing factor, particularly HIV-infection, is mandatory. The treatment of secondary syphilis, according to the Ministry of Health of Brazil proposal, foresees two series of 2,400,000 U of benzathine penicillin, with an interval of one week between the series. There is no mention of the scheme to be used for malignant syphilis and the literature mentions both three and four series regarding the use of crystalline penicillin. Strictly speaking, the definition of the treatment should attend to the coexistence or not of neurosyphilis or syphilitic uveitis. In this studied case, three series of 2,400,000 U of benzathine penicillin were fully effective.

In face of the increased number of syphilis cases, dermatologists and general practitioners should be attentive to the possibility of occurrence of malignant syphilis cases and equally attentive to the intensity of the Jarisch-Herxheimer reaction and for this reason to include antihistaminic drugs or even corticosteroids in the prescription prior to penicillin.

REFERENCES

1. Cordi M, Solari R, De Carolis L, Figureiras O, Vittor N, Maronna E. Sífilis maligna en un paciente con infección por VIH. Presentación de un caso y revisión de la literatura. Rev Chilena Infectol. 2012;29:678-81.
2. Watson KM, White JM, Salisbury JR, Creamer D. Lues maligna. Clin Exp Dermatol. 2004;29:825-7.
3. Belda Jr W, Dias MC, Zöll CA, Santos Junior MFQ, Siqueira LFG. Sífilis maligna precoce: a propósito de um caso. An Bras Dermatol. 1990;65:147-50.
4. Avetleira JCR, Rangel GCB. Sífilis: diagnóstico, tratamento e controle. An Bras Dermatol. 2000;81:111-26.
5. Tucker JD, Shah S, Jared AD, Tzai KY, Zembowicz A, Kroshinsky D. Lues maligna in early HIV infection case report and review of the literature. Sex Transm Dis. 2009;36:512-4.
6. Passoni LF, de Menezes JA, Ribeiro SR, Sampaio EC. Lues maligna in an HIV-infected patient. Rev Soc Bras Med Trop. 2005;38:181-4.
7. Schöfer H, Imhof M, Thoma-Greber E, Brockmeyer NH, Hartmann M, Gerken G, et al. Active syphilis in HIV infection: a multicentre retrospective survey. Genitourin Med. 1996;72:176-81.

How to cite this article: Requena CB, Orasmo CR, Ocanha JP, Barraviera SRCs, Marques MEA, Marques SA. Malignant syphilis in an immunocompetent female patient. An Bras Dermatol. 2014;89(6):806-7.